Amrutanjan Health Care Limited (AMRUTANJAN) — Board Meeting

1 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board approved audited results, dividend, director appointments, and ESOP 2.

🔄 What Changed
Final dividend of ₹2.90 per share; appointment of Mr. Ramaswami Krishnan as non-executive independent director; re-appointment of Mr. Muralidharan Swayambunathan for a second term; approval of revised ESOP 2 scheme.

🔮 What's Next
None

💡 Investor Takeaway
Shareholders will receive a ₹2.90 dividend per share if approved at the AGM, and new independent directors will join the board.

The board approved audited financial results for Q4 and FY2026, recommended a final dividend of ₹2.90 per share, appointed Mr. Ramaswami Krishnan as a non-executive independent director effective May 8, 2026, re-appointed Mr. Muralidharan Swayambunathan for a second term, and approved the revised ESOP 2 scheme. It also approved PKF Sridhar & Santhanam as internal auditors for 2026-27.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board approves revised ESOP 2 Phase for 200,000 employees

💡 Investor Takeaway
The new ESOP dilutes existing shares and may pressure future earnings per share.

Amrutanjan Health Care Limited announced on May 8, 2026 that its board approved the revised Second Phase of the Employees Stock Option Scheme 2020, granting 200,000 options to 44 mid‑level employees with a grant price of Rs 502 per share, 10% of which vest immediately, and implementation will occur via an ESOP Trust managed by Surana & Surana.

3 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board approves appointments of two non-executive independent directors.

🔄 What Changed
New appointments of Ramaswami Krishnan and re-appointment of Muralidharan Swayambunathan.

🔮 What's Next
None

💡 Investor Takeaway
These appointments strengthen governance but require shareholder approval before taking effect.

The board appointed Ramaswami Krishnan as an additional non-executive independent director effective 8 May 2026 for five years pending shareholder approval, and re-appointed Muralidharan Swayambunathan for a final five-year term starting 29 June 2026, also pending shareholder approval.

📊 Stock Analysis — AMRUTANJAN ✨ Ask AI About This